Drug profile · INN
shingles (herpes zoster) vaccine (live)
ZOSTAVAX
shingles (herpes zoster) vaccine (live) (ZOSTAVAX) is a biological vaccine - induces immune response.
EMA: withdrawn Antiinfectives for systemic use (J07) J07BK02
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — shingles (herpes zoster) vaccine (live)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
shingles (herpes zoster) vaccine (live) (ZOSTAVAX) is a biological vaccine - induces immune response.
Key facts
INN shingles (herpes zoster) vaccine (live)
Brand ZOSTAVAX
Mechanism Biological vaccine - induces immune response
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BK02
Mechanism of action
Biological vaccine - induces immune response
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is shingles (herpes zoster) vaccine (live)?
shingles (herpes zoster) vaccine (live) (ZOSTAVAX) is a biological vaccine - induces immune response.
What is the brand name for shingles (herpes zoster) vaccine (live)?
ZOSTAVAX is a marketed brand name for shingles (herpes zoster) vaccine (live). Check FDA Drugs@FDA for the current US label holder and prescribing information.